SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.
*mPFS: 11.53 months with SARCLISA + Pd vs 6.47 months with Pd alone, HR=0.596. ORR: 60.4% with SARCLISA + Pd (95% CI: 0.52, 0.68) vs 35.3% with Pd alone (95% CI: 0.28, 0.43), P<0.0001.1 A consistent benefit across subgroups was also demonstrated in the broad, diverse patient population.2
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
mAb=monoclonal antibody; mPFS=median progression-free survival; ORR=overall response rate; Pd=pomalidomide and dexamethasone.
References: 1. SARCLISA [summary of product characteristics]. sanofi-aventis groupe: Paris, France; May 2020. 2. Attal M, Richardson PG, Rajkumar SV, et al; on behalf of the ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107.
Review the Summary of Product Characteristics.